Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. A C20 fatty diacid moiety extends its half-life to support weekly dosing.

In clinical research it has been studied for glycemic control in type 2 diabetes (SURPASS program) and body weight reduction in adults with obesity (SURMOUNT program).

It is of interest as the first marketed dual incretin receptor agonist and is used as a reference compound in metabolic research on multi-receptor agonism.

For research purposes only. Not for human consumption.